BNET Industries
Abbott Laboratories Inc. (ABT) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $25.9B
- Profit
- Dec 31 2007
- $3.6B
- Market Cap
- Jul 17 2008
- $1.7M
Latest News and Analysis
Abbott Proves Successful in a Very Tough Market
Ockham Research submits: While many earnings reports these days are disconcerting to investors as fuel prices weigh on the economy, we think it is important to note those companies that are beating expectations. Beating estimates amidst tough circumstances is a sign of solid management, which is always a positive...
Abbott Labs Reports Stellar Earnings, Poised to Break New Highs
Mike Havrilla submits: Abbott Labs ABT posted better than expected earnings and sales growth and raised its guidance this morning, reflected in the 1-year stock chart posted on my blog which shows that the company has outperformed the S&P 500 index by over 30% and the Healthcare Sector SPDR exchange-traded...
Abbott Laboratories Q2 2008 Earnings Call Transcript
Abbott Laboratories ABT Q2 FY08 Earnings Call
Abbott Profit Tops Forecast; Drugs, Devices Shine
NEW YORK (Reuters) - Abbott Laboratories Inc ABT on Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales growth of its prescription drugs and medical devices. The suburban Chicago drugmaker said it earned $1.32 billion, or...
Earnings Preview: Abbott Laboratories
Abbott Laboratories ABT is expected to report Q2 earnings before market open on Wednesday, July 16, with a conference call scheduled July 16 for 9:00 am ET. Guidance Analysts are looking for a profit of 79c on revenue of $7.23B. The consensus range is 76c to 79c for EPS, and...
July's Top Dividend Buys
Stockerblog submits: If you are looking for dividend buys, here are some stocks going ex-dividend during the last half of July. Most of the following stocks have a PE below 20, all have PEG ratios below 2.5, and yields over 2.5%.First Defiance Financial FDEF 7/9/2008 Yield: 6.62% P/E: 8...
Boston Scientific Bundles Stents with Defibrillators and Ultrasound
Mike Huckman submits: FBR's Christopher Warren was out with a research note to clients Friday morning saying that Boston Scientific BSX is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices." Taxus is the name of Boston...
22 Stocks Going Ex-Dividend in Early July
Stockerblog submits: I've received questions recently about all the stock dividend dates, so I thought I would clarify them for you. In addition, for those who are interested in 'buying dividends,' I have listed the stocks going ex-dividend during the first two weeks of July. Here's what each of...
Abbott Labs: Dividend Analysis
Dobromir Stoyanov submits: Abbott Laboratories ABT engages in the development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Abbott Laboratories is a dividend aristocrat as well as a component of the S&P 500 index. It has...
Most and Least Shorted Stocks in the Russell 1,000
Hickey and Walters Bespoke submit: With the S&P 500 down this year, it's no surprise that the most heavily shorted stocks when compared to their equity floats are down significantly as well. As shown below, NutriSystem NTRI is the most heavily shorted stock in the Russell 1,000, with...
Abbott Laboratories Q1 2008 Earnings Call Transcript
Abbott Laboratories Q1 2008 Earnings Call Transcript
Abbott Laboratories Q4 2007 Earnings Call Transcript
Abbott Laboratories Q4 2007 Earnings Call Transcript
Abbott Laboratories Q3 2007 Earnings Call Transcript
Abbott Laboratories Q3 2007 Earnings Call Transcript
Abbott Laboratories Q2 2007 Earnings Call Transcript
Abbott Laboratories Q2 2007 Earnings Call Transcript
Abbott Laboratories Q2 2007 Earnings Call Transcript
Abbott Laboratories Q2 2007 Earnings Call Transcript
Additional Resources
BellwetherReport.com Analyst Report on ABT, FDG, NUE and OCTL
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
Antares Pharma Appoints Paul Wotton, Ph.D. as President and Chief Operating Officer
EWING, N.J. -- Antares Pharma, Inc. (AMEX:AIS) announced that Paul K. Wotton, Ph.D., has joined Antares Pharma as President and Chief Operating Officer. Dr. Wotton has over 20 years experience in the pharmaceutical industry with both large and specialty pharma companies. Previously, Dr. Wotton served as CEO of...
Seven Summits Research Releases Comments on AA, ABT, STZ, SGR and PBG
CHICAGO, July 7 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide. The Seven Summits Strategic Investments Stocks To Watch Guide (go to: http://www.iotogo.com/StocksToWatch) provides investors with essential information on stocks that may be poised for a significant move. By featuring hedged...
New Drug-Coated Stent Approved
The Xience drug-coated stent, used to prop open a blocked or narrowed artery in people with coronary artery disease, has been approved by the U.S. Food and Drug Administration, maker Abbott Laboratories said. A stent is a metal-mesh tube that's inserted into the artery. The drug, everolimus, helps prevent the...
Learn about the World Molecular Diagnostics Market
Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue. World Molecular Diagnostics Market http://www.reportlinker.com/p090566/World-Molecular-Diagnostics-Market.html This report analyzes the worldwide markets for Molecular Diagnostics in Millions of US$. The specific product segments analyzed are Infectious Disease...
- Next »
- page 1 of 168
- « Previous
Sort byClose
- Incorporated: 1900
- CEO: Mr. Miles D. White
Abbott Laboratories is principally engaged in the discovery, development, manufacture and sale of a variety of health care products through four business segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Co.'s primary products are prescription pharmaceuticals, nutritional products, vascular products and diagnostic testing products. In addition, Co. has a 50.0%-owned joint-venture, TAP Pharmaceutical Products Inc. with Takeda Pharmaceutical Company Ltd. of Japan, through which Co. develops, markets and sells pharmaceutical products such as Lupron®, Lupron Depot® and Prevacid® (lansoprazole), within the U.S., Puerto Rico and Canada.
Key Competitors
Abbott Laboratories Inc. Company Info
Board of Directors
Mr. Miles D. White
Chairman
Mr. Roy S. Roberts
Mr. Samuel C. Scott III
Mr. William D. Smithburg
Mr. Glenn F. Tilton
Ms. Roxanne S. Austin
Mr. William M. Daley
Mr. W. James Farrell
Mr. H. Laurance Fuller
Mr. William A. Osborn
The Rt. Hon. Lord David Owen
Mr. Boone Powell Jr.
Dr. W. Ann Reynolds Ph.D.
Contact Information
100 Abbott Park Road
Abbott Park, IL
847 937-6100
